source
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…BioSpace · 1d ago↗ source
- Jury awards $6 million to former MIT professor David Sabatini in defamation caseA Suffolk County jury awarded $6 million in damages to former MIT professor David Sabatini after finding the plaintiff's claims were defamatory. The case stemmed from accusations by a younger coll…
- Revolution Medicines' pancreatic cancer therapy Rasonque moves closer to European approval after FDA clearance